Decitabine triphosphate levels in peripheral blood mononuclear cells from patients receiving prolonged low-dose decitabine administration: A pilot study

Cancer Chemotherapy and Pharmacology

Volumn 69, Issue 6, 2012, Pages 1457-1466

  Jansen, Robert S ^a   Rosing, Hilde ^a   Wijermans, Pierre W ^b   Keizer, Ron J ^a   Schellens, Jan H M ^c,d   Beijnen, Jos H ^a,d  

^a SLOTERVAART HOSPITAL   (Netherlands)

^b HAGA HOSPITAL   (Netherlands)

^c NETHERLANDS CANCER INSTITUTE   (Netherlands)

^d UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Decitabine; LC MS; Myelodysplastic syndromes; Nucleotide analogs; Resistance

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; DECITABINE TRIPHOSPHATE; DRUG METABOLITE; UNCLASSIFIED DRUG;

ARTICLE; BLOOD SAMPLING; CANCER PATIENT; CELL LEVEL; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG DETERMINATION; EX VIVO STUDY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; LOW DRUG DOSE; MASS SPECTROMETRY; MULTIPLE CYCLE TREATMENT; PERIPHERAL BLOOD MONONUCLEAR CELL; PILOT STUDY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; TREATMENT DURATION; TREATMENT RESPONSE;

ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; CHROMATOGRAPHY, LIQUID; HUMANS; LEUKOCYTES, MONONUCLEAR; MYELODYSPLASTIC SYNDROMES; PILOT PROJECTS; TANDEM MASS SPECTROMETRY;

EID: 84863802864     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-012-1850-x     Document Type: Article

References (53)

1. Aparicio A, Eads CA, Leong LA, Laird PW, Newman EM, Synold TW et al (2003) Phase I trial of continuous infusion 5-aza-2'- deoxycytidine. Cancer Chemother Pharmacol 51:231-239
2. Beausejour CM, Gagnon J, Primeau M, Momparler RL (2002) Cytotoxic activity of 2',2'-difluorodeoxycytidine, 5-aza-2'-deoxycytidine and cytosine arabinoside in cells transduced with deoxycytidine kinase gene. Biochem Biophys Res Commun 293:1478-1484
3. Cashen AF, Shah AK, Todt L, Fisher N, DiPersio J (2008) Pharmacokinetics of decitabine administered as a 3-h infusion to patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Cancer Chemother Pharmacol 61:759-766
4. Chabot GG, Bouchard J, Momparler RL (1983) Kinetics of deamination of 5-aza-2'-deoxycytidine and cytosine arabinoside by human liver cytidine deaminase and its inhibition by 3-deazauridine, thymidine or uracil arabinoside. Biochem Pharmacol 32:1327-1328
5. Cihak A (1978) Transformation of 5-aza-2'-deoxycytidine-3H and its incorporation in different systems of rapidly proliferating cells. Eur J Cancer 14:117-124
6. Daskalakis M, Nguyen TT, Nguyen C, Guldberg P, Kohler G, Wijermans P et al (2002) Demethylation of a hypermethylated P15/ INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2'- deoxycytidine (decitabine) treatment. Blood 100:2957-2964
7. Eliopoulos N, Cournoyer D, Momparler RL (1998) Drug resistance to 5-aza-2'-deoxycytidine, 2',2'-difluorodeoxycytidine, and cytosine arabinoside conferred by retroviral-mediated transfer of human cytidine deaminase cDNA into murine cells. Cancer Chemother Pharmacol 42:373-378
8. Gandhi V, Xu YZ, Estey E (1998) Accumulation of arabinosyluracil 5'-triphosphate during arabinosylcytosine therapy in circulating blasts of patients with acute myelogenous leukemia. Clin Cancer Res 4:1719-1726
9. Grant S, Rauscher F III, Margolin J, Cadman E (1982) Dose- and schedule-dependent activation and drug synergism between thymidine and 5-aza-2'-deoxycytidine in a human promyelocytic leukemia cell line. Cancer Res 42:519-524
10. Grunewald R, Kantarjian H, Keating MJ, Abbruzzese JL, TarassoV P, Plunkett W (1990) Pharmacologically directed design of the dose rate and schedule of 2',2'-difluorodeoxycytidine (Gemcitabine) administration in leukemia. Cancer Res 50:6823-6826
11. Hackanson B, Robbel C, Wijermans P, Lubbert M (2005) In vivo effects of decitabine in myelodysplasia and acute myeloid leukemia: review of cytogenetic and molecular studies. Ann Hematol 84(Suppl 1):32-38
12. Issa JP (2007) DNA methylation as a therapeutic target in cancer. Clin Cancer Res 13:1634-1637
13. Issa JP, Garcia-Manero G, Giles FJ, Mannari R, Thomas D, Faderl S et al (2004) Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies. Blood 103:1635-1640
14. Jabbour E, Issa JP, Garcia-Manero G, Kantarjian H (2008) Evolution of decitabine development: accomplishments, ongoing investigations, and future strategies. Cancer 112:2341-2351
15. Jansen RS, Rosing H, de Wolf CJ, Beijnen JH (2007) Development and validation of an assay for the quantitative determination of cladribine nucleotides in MDCKII cells and culture medium using weak anion-exchange liquid chromatography coupled with tandem mass spectrometry. Rapid Commun Mass Spectrom 21: 4049-4059
16. Jansen RS, Rosing H, Schellens JH, Beijnen JH (2009) Retention studies of 2'-2'-difluorodeoxycytidine and 2'-2'-difluorodeoxyuridine nucleosides and nucleotides on porous graphitic carbon: development of a liquid chromatography-tandem mass spectrometry method. J Chromatogr A 1216:3168-3174
17. Jansen RS, Rosing H, Schellens JH, Beijnen JH (2011) Mass spectrometry in the quantitative analysis of therapeutic intracellular nucleotide analogs. Mass Spectrom Rev 30:321-343
18. Jordheim L, Galmarini CM, Dumontet C (2003) Drug resistance to cytotoxic nucleoside analogues. Curr Drug Targets 4:443-460
19. Kantarjian H, Issa JP, Rosenfeld CS, Bennett JM, Albitar M, DiPersio J et al (2006) Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 106:1794-1803
20. Kantarjian H, Oki Y, Garcia-Manero G, Huang X, O'Brien S, Cortes J et al (2007) Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 109:52-57
21. Kantarjian HM, Issa JP (2005) Decitabine dosing schedules. Semin Hematol 42:S17-S22
22. Laliberte J, Marquez VE, Momparler RL (1992) Potent inhibitors for the deamination of cytosine arabinoside and 5-aza-2'-deoxycytidine by human cytidine deaminase. Cancer Chemother Pharmacol 30:7-11
23. Lemaire M, Chabot GG, Raynal NJ, Momparler LF, Hurtubise A, Bernstein ML et al (2008) Importance of dose-schedule of 5-aza-2'- deoxycytidine for epigenetic therapy of cancer. BMC Cancer 8:128
24. Lemaire M, Momparler LF, Raynal NJ, Bernstein ML, Momparler RL (2009) Inhibition of cytidine deaminase by zebularine enhances the antineoplastic action of 5-aza-2'-deoxycytidine. Cancer Chemother Pharmacol 63:411-416
25. Lin KT, Momparler RL, Rivard GE (1981) High-performance liquid chromatographic analysis of chemical stability of 5-aza-2'- deoxycytidine. J Pharm Sci 70:1228-1232
26. Liu Z, Marcucci G, Byrd JC, Grever M, Xiao J, Chan KK (2006) Characterization of decomposition products and preclinical and low dose clinical pharmacokinetics of decitabine (5-aza-2'-deoxycytidine) by a new liquid chromatography/tandem mass spectrometry quantification method. Rapid Commun Mass Spectrom 20:1117-1126
27. Momparler RL (2005) Pharmacology of 5-Aza-2'-deoxycytidine (decitabine). Semin Hematol 42:S9-S16
28. Momparler RL (1985) Molecular, cellular and animal pharmacology of 5-aza-2'-deoxycytidine. Pharmacol Ther 30:287-299
29. Momparler RL, Bouffard DY, Momparler LF, Dionne J, Belanger K, Ayoub J (1997) Pilot phase I-II study on 5-aza-2'-deoxycytidine (Decitabine) in patients with metastatic lung cancer. Anticancer Drugs 8:358-368
30. Momparler RL, Chu MY, Fischer GA (1968) Studies on a new mechanism of resistance of L5178Y murine leukemia cells to cytosine arabinoside. Biochim Biophys Acta 161:481-493
31. Momparler RL, Cote S, Eliopoulos N (1997) Pharmacological approach for optimization of the dose schedule of 5-Aza-2'-deoxycytidine (Decitabine) for the therapy of leukemia. Leukemia 11:175-180
32. Momparler RL, Momparler LF (1989) Chemotherapy of L1210 and L1210/ARA-C leukemia with 5-aza-2'-deoxycytidine and 3-deazauridine. Cancer Chemother Pharmacol 25:51-54
33. Momparler RL, Rivard GE, Gyger M (1985) Clinical trial on 5-aza-2'-deoxycytidine in patients with acute leukemia. Pharmacol Ther 30:277-286
34. Momparler RL, Rossi M, Bouchard J, Bartolucci S, Momparler LF, Raia CA et al (1986) 5-AZA-2'-deoxycytidine synergistic action with thymidine on leukemic cells and interaction of 5-AZAdCMP with dCMP deaminase. Adv Exp Med Biol 195(Pt B):157-163
35. Momparler RL, Rossi M, Bouchard J, Vaccaro C, Momparler LF, Bartolucci S (1984) Kinetic interaction of 5-AZA-2'-deoxycytidine- 5'-monophosphate and its 5'-triphosphate with deoxycytidylate deaminase. Mol Pharmacol 25:436-440
36. Oki Y, Aoki E, Issa JP (2007) Decitabine-bedside to bench. Crit Rev Oncol Hematol 61:140-152
37. Oki Y, Jelinek J, Shen L, Kantarjian HM, Issa JP (2008) Induction of hypomethylation and molecular response after decitabine therapy in patients with chronic myelomonocytic leukemia. Blood 111:2382-2384
38. Patel K, Guichard SM, Jodrell DI (2008) Simultaneous determination of decitabine and vorinostat (Suberoylanalide hydroxamic acid, SAHA) by liquid chromatography tandem mass spectrometry for clinical studies. J Chromatogr B Anal Technol Biomed Life Sci 863:19-25
39. Qin T, Castoro R, El Ahdab S, Jelinek J, Wang X, Si J et al (2011) Mechanisms of resistance to decitabine in the myelodysplastic syndrome. PLoS One 6:e23372
40. Qin T, Jelinek J, Si J, Shu J, Issa JP (2009) Mechanisms of resistance to 5-aza-2'-deoxycytidine in human cancer cell lines. Blood 113:659-667
41. Qin T, Youssef EM, Jelinek J, Chen R, Yang AS, Garcia-Manero G et al (2007) EVect of cytarabine and decitabine in combination in human leukemic cell lines. Clin Cancer Res 13:4225-4232
42. Rivard GE, Momparler RL, Demers J, Benoit P, Raymond R, Lin K et al (1981) Phase I study on 5-aza-2'-deoxycytidine in children with acute leukemia. Leuk Res 5:453-462
43. Ruter B, Wijermans PW, Lubbert M (2006) Superiority of prolonged low-dose azanucleoside administration? Results of 5-aza- 2'-deoxycytidine retreatment in high-risk myelodysplasia patients. Cancer 106:1744-1750
44. Steensma DP, Baer MR, Slack JL, Buckstein R, Godley LA, Garcia- Manero G et al (2009) Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial. J Clin Oncol 27:3842-3848
45. Stegmann AP, Honders MW, Hagemeijer A, Hoebee B, Willemze R, Landegent JE (1995) In vitro-induced resistance to the deoxycytidine analogues cytarabine (AraC) and 5-aza-2'-deoxycytidine (DAC) in a rat model for acute myeloid leukemia is mediated by mutations in the deoxycytidine kinase (dck) gene. Ann Hematol 71:41-47
46. van Groeningen CJ, Leyva A, O'Brien AM, Gall HE, Pinedo HM (1986) Phase I and pharmacokinetic study of 5-aza-2'-deoxycytidine (NSC 127716) in cancer patients. Cancer Res 46:4831-4836
47. Veltkamp SA, Hillebrand MJ, Rosing H, Jansen RS, Wickremsinhe ER, Perkins EJ et al (2006) Quantitative analysis of gemcitabine triphosphate in human peripheral blood mononuclear cells using weak anion-exchange liquid chromatography coupled with tandem mass spectrometry. J Mass Spectrom 41:1633-1642
48. Veltkamp SA, Jansen RS, Callies S, Pluim D, Visseren-Grul CM, Rosing H et al (2008) Oral administration of gemcitabine in patients with refractory tumors: a clinical and pharmacologic study. Clin Cancer Res 14:3477-3486
49. Veltkamp SA, Pluim D, van Eijndhoven MA, Bolijn MJ, Ong FH, Govindarajan R et al (2008) New insights into the pharmacology and cytotoxicity of gemcitabine and 2',2'-difluorodeoxyuridine. Mol Cancer Ther 7:2415-2425
50. Veltkamp SA, Pluim D, van Tellingen O, Beijnen JH, Schellens JH (2008) Extensive metabolism and hepatic accumulation of gemcitabine after multiple oral and intravenous administration in mice. Drug Metab Dispos 36:1606-1615
51. Wang LH, Begley J, St CR III, Harris J, Wakeford C, Rousseau FS (2004) Pharmacokinetic and pharmacodynamic characteristics of emtricitabine support its once daily dosing for the treatment of HIV infection. AIDS Res Hum Retroviruses 20:1173-1182
52. Wijermans PW, Krulder JW, Huijgens PC, Neve P (1997) Continuous infusion of low-dose 5-Aza-2'-deoxycytidine in elderly patients with high-risk myelodysplastic syndrome. Leukemia 11:1-5
53. Yang AS, Doshi KD, Choi SW, Mason JB, Mannari RK, Gharybian V et al (2006) DNA methylation changes after 5-aza-2'-deoxycytidine therapy in patients with leukemia. Cancer Res 66:5495-5503